SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
LATEST POSTS
- 1
Changing Negative Cash Mentalities: Enabling Your Monetary Excursion - 2Newly identified species of Tanzanian tree toad leapfrog the tadpole stage and give birth to toadlets
- 3Blue Origin's next space tourism flight will break new ground for people with disabilities
- 4Woman gives birth on roadside after hospital allegedly sent her home: Family
- 5One of the best meteor showers of the year peaks at the worst possible time this week
- Banks for High Fixed Store Rates: Amplify Your Reserve funds
- Did we start the fire? A 400,000-year-old hearth sparks new questions about human evolution
- Famous Places to get-away for Americans
- Productive CRM Programming for Client Relationship The executives
- New York to require social media platforms to display mental health warnings
- Find the Standards of Viable Refereeing: Settling Debates with Strategy
- Dramatic Dominance d: A Survey of \Feelings in front of an audience\ Theater Play
- Kids get diseases like lupus, too. As researchers hunt better treatments, this camp brings joy
- Tech for Efficiency: Applications and Apparatuses to Accomplish More
